Finnish Blood Testing Startup Is Going Beyond The Theranos Dream

Finnish blood testing startup Nightingale is looking to solve the global burden of chronic disease. In the US, 86% of the $2.7 trillion annual health budget is spent on chronic disease, and with their Nuclear Magnetic Resonance based biomarker analysis assay, Nightingale is looking to reinvent chronic disease screening, diagnostics and treatment efficacy.